Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the effect of selonsertib (formerly
GS-4997) on estimated glomerular filtration rate (eGFR) decline in participants with diabetic
kidney disease (DKD). Participants will be randomized with a 1:1:1:1 allocation to receive 1
of 3 doses of selonsertib (2 mg, 6 mg, or 18 mg) or matching placebo.